Table 2.
Clinical and demographic data
| Characteristic | Cefepime | Cefepime-amikacin | Cefepime-levofloxacin |
| Number of evaluable patients | 20 | 19 | 20 |
| Mean age (years) | 53.1 ± 22.1 | 64.7 ± 19.1 | 59.2 ± 14.8 |
| Gender (male/female) | 13/7 | 10/9 | 15/5 |
| Trauma | 9 | 9 | 5 |
| Cardiac surgery | 4 | 5 | 6 |
| Postoperative respiratory failure | 2 | 1 | 4 |
| Intracranial bleeding | 3 | 3 | 4 |
| Cardiac arrest | 1 | 1 | 0 |
| Haemorrhagic shock | 1 | 0 | 1 |
| ICU LOS (days): mean ± SD (median) | 26 ± 23.1(21) | 23 ± 7.9 (22.5) | 34.7 ± 53.4 (20) |
| Hospital LOS before VAP (days): mean ± SD (median) | 9 ± 6.4 (7) | 11.3 ± 9.1 (8) | 12.2 ± 12.3 (9) |
| Mean length of ventilatory support before VAP (days): mean ± SD (median) | 7.2 ± 6.1 (6) | 6.5 ± 2.1 (6) | 9.4 ± 10.7 (5) |
| Mean APACHE II score | 17.1 ± 4.6 | 14.6 ± 6.8 | 16.5 ± 6.4 |
| SOFA score at day of infection | 6.9 | 7 | 7.3 |
| SOFA MAX | 8.7 ± 3.3 | 9.6 ± 3.7 | 10 ± 3.3 |
ICU, intensive care unit; LOS, length of stay; SD, standard deviation; SOFA, sequential organ failure assessment; VAP, ventilator acquired pneumonia.